impact:

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

According to PR-model, Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies is ranked 1,526,555th in multilingual Wikipedia, in particular this website is ranked 1,215,300th in English Wikipedia.

#Language
PR-model F-model AR-model
1,526,555th place
1,427,977th place
1,610,452nd place
1,215,300th place
827,334th place
1,273,313th place